52574-06-8

Usage

Uses

Used in Biomedical Research:
1-Methyl-5-oxo-L-Proline is utilized as a research compound for investigating its interactions and effects within biological systems, particularly in the context of neurological conditions. Its structural similarity to proline may offer insights into the role of amino acids in neurological health and disease.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-Methyl-5-oxo-L-Proline is considered as a potential therapeutic agent, especially for conditions related to the nervous system. Its unique structure may contribute to the development of novel drugs that could target specific neurological pathways or mechanisms, thereby providing new treatment options for patients.
Used in Drug Delivery Systems:
1-Methyl-5-oxo-L-Proline may also be explored for its potential use in drug delivery systems, where its chemical properties could be leveraged to improve the efficacy and bioavailability of other pharmaceutical compounds, particularly those aimed at treating neurological disorders. The development of such systems could enhance the therapeutic outcomes for patients by ensuring more effective drug delivery to target areas within the body.

Upstream product

• 42435-88-1 (S)-methyl 1-methyl-5-oxopyrrolidine-2-carboxylate 
• 146963-42-0 N-methyl-L-2-oxopyrrolidine-5-carboxylic acid benzyl ester 
• 6753-62-4 N-methyl-L-glutamic acid 
• 177314-35-1 1-methyl-L-pyroglutamic acid ethyl ester 
• 190783-99-4 (S)-methyl 1-methyl-5-oxopyrrolidine-2-carboxylate 
• 35418-16-7 L-t-butyl pyroglutamate 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 146963-39-5 N-(o-nitrobenzyl)-L-glutamic acid dibenzyl ester 
• 146963-40-8 N-methyl-N-(o-nitrobenzyl)-L-glutamic acid dibenzyl ester 
• 146963-43-1 (S)-2-{[1-(2-Nitro-phenyl)-meth-(E)-ylidene]-amino}-pentanedioic acid dibenzyl ester 
• 146963-41-9 N-methyl-L-glutamic acid dibenzyl ester 
• 4561-10-8 L-glutamic acid dibenzyl ester hydrochloride 

Downstream Products

• 76854-63-2 6-[4-(N-methyl-5-oxo-L-prolyl)amino]phenyl-1,2-dihydro-2-oxonicotinic acid 
• 1001389-32-7 C₁₃H₁₄ClFN₂O₂ 
• 1448345-68-3 C₂₄H₂₃ClF₃N₃O₃ 
• 42435-90-5 1-methyl-5-oxoprolyl chloride 

Relevant academic research and scientific papers

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening Approach

Employing a virtual screening approach, we identified the pyroglutamide moiety as a nonacid replacement for the cyclohexanecarboxylic acid group which, when coupled to our previously reported conformationally locked tricyclic core, provided potent and selective RORγt inverse agonists. Structure-activity relationship optimization of the pyroglutamide moiety led to the identification of compound 18 as a potent and selective RORγt inverse agonist, albeit with poor aqueous solubility. We took advantage of the tertiary carbinol group in 18 to synthesize a phosphate prodrug, which provided good solubility, excellent exposures in mouse PK studies, and significant efficacy in a mouse model of psoriasis.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

SUBSTITUTED PYRIDOXINE-LACTAM CARBOXYLATE SALTS

The present invention provides salt adducts comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, methods of their preparation, and pharmaceutical compositions and medicaments comprising them. Salt adducts of the invention and compositions comprising them may be used to in the treatment of diseases or disorders associated with or inflicted by alcohol consumption.

Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X7 receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X7 antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies.

Kendarimide A, a novel peptide reversing P-glycoprotein-mediated multidrug resistance in tumor cells, from a marine sponge of Haliclona sp.

A novel modulator of multidrug resistance (MDR) in tumor cells, kendarimide A (1), was isolated from an Indonesian marine sponge of Haliclona sp. Compound 1 reversed MDR in KB-C2 cells mediated by P-glycoprotein (P-gp) at a 6 μM concentration, and the chemical structure of 1 was characterized to be a linear peptide composed of N-methylpyroglutamic acid (pyroMeGlu), N-methylated eight-membered cysteinyl-cysteine (ox-[MeCys-MeCys]) together with many N-methyl amino acid residues. The amino acid sequence of 1 was determined by 2D NMR and FAB MS analysis. The absolute configuration of the amino acid residues in 1 except for the MeCys part was determined to be L-form respectively, based on interpretation of the HPLC analysis of Marfey's derivatives of the hydrolysates of 1 and the synthetic method for the pyroMeGlu residue.